12:00 AM
Jan 31, 2000
 |  BC Week In Review  |  Company News  |  Deals

Xoma, Baxter Healthcare Corp. deal

BAX's Baxter Hyland Immuno division (Munich, Germany) received exclusive worldwide rights to XOMA's Neuprex bactericidal/permeability-increasing protein for bacterial and endotoxin-related indications. The product has...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >